EGFR and non-small cell lung carcinoma: Fearing possible toxicities of a triple combination the RTOG 1306 phase II randomized trial is currently assessing the impact on progression free survival of these targeted agents (either erlotinib for EGFR mutated tumors or crizotinib for ALK translocated tumors) before concurrent chemoradiotherapy in patients with stage III Non-small Cell Lung Cancer (ClinicalTrials.gov identifier: NCT01822496) but the question of concomitant triple combination deserves cautious assessment and could open the way for new improvements.